Key Highlights

  • BEXMAB trial data showed median overall survival not yet reached in TP53 wild-type and monoallelic frontline HR-MDS patients at 14.9 months' follow-up.
  • Faron completed a EUR 40.1 million gross rights issue in April 2026, roughly 52.3% subscribed by shareholders.
  • The FY2025 accounts carried a going-concern warning, with cash flagged as sufficient only until Q2 2026 before the raise.
  • Earlier ESMO 2025 data showed an 85% objective response rate and 45% complete remission rate in treatment-naive patients.
  • Nasdaq Helsinki fined Faron EUR 30,000 in 2026 for late disclosure relating to 2024 conduct.

New BEXMAB trial data show frontline blood-cancer patients living longer on Faron's antibody bexmarilimab, but a going-concern warning, a discounted rights issue and a regulator fine complicate the Investment case.

Faron Pharmaceuticals (LSE:FARN), the Turku-based, dual-listed biotech developing the immuno-oncology antibody bexmarilimab, has delivered the clinical update investors have been waiting for. On 27 July 2026 it reported the first overall survival data from frontline higher-risk myelodysplastic syndrome (HR-MDS) patients in its BEXMAB Phase 1/2 trial. The news lands against a messier corporate backdrop: a EUR 40.1 million rights issue completed in April, a going-concern warning in the 2025 accounts, and a EUR 30,000 fine from Nasdaq Helsinki's disciplinary committee for late disclosure.

What Happened

Faron's 27 July release covered 21 treatment-naïve HR-MDS patients dosed with bexmarilimab plus azacitidine, at a median follow-up of 14.9 months. Patients with biallelic TP53 mutations — the hardest-to-treat, worst-prognosis subgroup — had a median overall survival of 8.8 months, broadly in line with historical benchmarks. Critically, median overall survival had not yet been reached in patients with monoallelic TP53 mutations or TP53 wild-type disease, meaning more than half were still alive at the data cut. Chief Medical Officer Dr Petri Bono said the results "further support the potential of bexmarilimab in frontline TP53 wild-type and mutated HR-MDS patients, where significant unmet medical need remains." Faron plans a randomised BEXERA study and will present the full BEXMAB dataset at an upcoming scientific meeting.

This followed readouts at ASCO in June 2025 and, more substantively, ESMO in October 2025, where Faron reported an 85% objective response rate and 45% complete remission rate in 20 evaluable treatment-naïve patients. In the relapsed/refractory, HMA-failed cohort (32 patients), ORR was 63% and median overall survival 13.4 months; 23% of BEXMAB patients overall were bridged to a potentially curative stem cell transplant.

Why It Matters

MDS is a group of bone-marrow cancers that frequently progresses to acute myeloid leukaemia; higher-risk patients, especially those with TP53 mutations, have historically had few Options and poor survival on hypomethylating-agent therapy alone. Bexmarilimab targets Clever-1, a receptor on immunosuppressive macrophages, aiming to convert the tumour microenvironment from "cold" to "hot" and restore anti-tumour immune activity. If the survival advantage in TP53 wild-type and monoallelic patients holds up, it would differentiate bexmarilimab from azacitidine alone and support a randomised, controlled study — the step regulators and pharma partners want before any approval or licensing deal becomes credible.

Latest Financial and Operational Performance

Faron remains pre-revenue. For full-year 2025 it reported EUR 1.3 million of other Operating Income (2024: nil), R&D expenses of EUR 12.7 million (2024: EUR 11.7 million), and administrative expenses of EUR 7.6 million (2024: EUR 6.9 million). The operating loss was EUR 19.0 million (2024: EUR 18.7 million), with a comprehensive loss of EUR 27.2 million and a loss per share of EUR 0.24. Cash stood at EUR 12.3 million at 31 December 2025 (2024: EUR 9.5 million), but directors flagged resources sufficient only "until Q2 2026" and disclosed "material uncertainty that may cast significant doubt on Faron's ability to continue as Going Concern ."

Faron plugged the gap with a EUR 15 million Convertible Bond from Heights Capital Management (April 2025, maturing 2028), a second EUR 10 million Tranche (December 2025, maturing 2028), and a EUR 40.1 million gross (EUR 32.8 million net) rights issue completed in April 2026, roughly 52.3% subscribed by shareholders and covered by guarantors for the balance. Shares in issue rose from 119,472,660 to 199,472,660, and have since risen to 227,881,315 as Faron settled bond Amortisation in new shares rather than cash.

Key Numbers

  • FY2025 R&D expenses: EUR 12.7 million (2024: EUR 11.7 million)
  • FY2025 operating loss: EUR 19.0 million; comprehensive loss: EUR 27.2 million
  • Cash at 31 December 2025: EUR 12.3 million; runway flagged only to Q2 2026
  • Rights issue (April 2026): EUR 40.1 million gross / c. EUR 32.8 million net, ~52.3% subscribed
  • BEXMAB frontline HR-MDS: 85% ORR, 45% CR rate (20 evaluable patients, ESMO 2025)
  • BEXMAB relapsed/refractory cohort: 63% ORR, 13.4-month median OS (32 patients)
  • Biallelic TP53 frontline subgroup: 8.8-month median OS at 14.9-month follow-up

Growth Opportunities

Net proceeds are earmarked for a randomised, roughly 90-patient Phase II trial of bexmarilimab plus azacitidine in frontline HR-MDS (BEXERA) and for accelerating up to five investigator-initiated trials (IITs) beyond MDS: BLAZE, pairing bexmarilimab with nivolumab in checkpoint-resistant lung cancer and melanoma with the Institute of Cancer Research and Royal Marsden; BEXAR, combining it with doxorubicin in first-line soft-tissue sarcoma; a City of Hope-led relapsed/refractory MDS study; and a BEAM-X study in post-transplant AML. A sixth FINPROVE cohort will not proceed. Each successful IIT broadens the evidence base at limited cost to Faron.

Risks Investors Should Know

The going-concern language in the FY2025 accounts is not boilerplate caution — cash was flagged as covering operations only into Q2 2026 before the rights issue closed, and Faron continues relying on dilutive Equity , including settling bond repayments in shares rather than cash. The rights issue was only about half subscribed by existing shareholders, the shortfall covered by guarantors, suggesting limited organic Demand at the offer terms. Clinically, the biallelic TP53 subgroup showed no survival benefit over historical norms, a reminder that benefit may be concentrated in specific molecular subgroups. Separately, Nasdaq Helsinki fined Faron EUR 30,000 in 2026 for breaching disclosure obligations relating to 2024 conduct.

What to Watch Next

Investors should watch for the full BEXMAB dataset at an upcoming scientific meeting, first-patient enrolment for BLAZE and BEXAR, enrolment progress for BEXERA, and cash-runway detail once BEXERA costs are layered onto existing spend. Continued reliance on share-settled bond amortisation is worth tracking as a signal of underlying cash generation.

Outlook

Faron's latest BEXMAB data give bexmarilimab a genuine, if early, survival signal in a genetically-defined subset of higher-risk MDS patients — a meaningful step for a mechanism, anti-Clever-1 macrophage reprogramming, that has yet to produce an approved therapy. But the clinical narrative cannot be separated from the financial one: a company that needed a rights issue to fund its next trial, still discloses going-concern risk, and has drawn a disclosure fine is asking investors to look past near-term dilution for longer-term clinical validation. Whether the survival benefit widens with more mature data, and whether Faron can fund its way there without further heavy dilution, will determine which story prevails.